Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

434
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
434
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

483
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
483
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

200
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
200
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

232
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
232
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

207
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
207
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

257
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
257

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Preterm infant formulas with glucose polymers and reduced lactose content increase the risk of necrotizing enterocolitis.

Frontiers in nutrition·2026
Same author

Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. <i>Cancers</i> 2026, <i>18</i>, 124.

Cancers·2026
Same author

The Price of Survival: Global Inequities in Anti-GD2 Immunotherapy for Neuroblastoma.

Pediatric blood & cancer·2026
Same author

High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry.

Cancers·2026
Same author

National data for global 2030 targets for childhood cancer.

Lancet (London, England)·2025
Same author

Methotrexate nephrotoxicity: a pragmatic approach.

Current opinion in nephrology and hypertension·2025
Same journal

Metabolic Syndrome and Risk of Atrial Fibrillation in Chronic Kidney Disease.

American journal of nephrology·2026
Same journal

Premature Aortic Stiffness in Relation to Cerebral Small Vessel Disease, Cognitive Decline, Major Cardiovascular Events and Mortality in Dialysis.

American journal of nephrology·2026
Same journal

Adjudicating heart failure as an end point in dialysis trials- more signal, less noise.

American journal of nephrology·2026
Same journal

Bridging the Evidence-to-Practice Gap in Hypertension: Why Innovation Isn't Always Implementation.

American journal of nephrology·2026
Same journal

Adjudicating Heart Failure Events in Participants Receiving Hemodialysis: Findings from Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

American journal of nephrology·2026
Same journal

Beyond the Amount: The Selectivity of Proteinuria and Risk of Graft Failure in Kidney Transplant Recipients.

American journal of nephrology·2026
查看所有相关文章

相关实验视频

Updated: Jan 14, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.2K

高剂量甲基甲酸盐的毒性 高剂量甲基甲酸盐的毒性

Jaya Kala1, Scott C Howard2,3,4

  • 1Division of Nephrology, Department of Internal Medicine, University of Texas Health Science Center-McGovern Medical School, Houston, Texas, USA.

American journal of nephrology
|October 24, 2025
PubMed
概括
此摘要是机器生成的。

高剂量的甲状腺素 (HDMTX) 可以导致损伤. 及时识别和管理延迟排泄和功能障碍对于预防严重毒性和改善患者结果至关重要.

关键词:
急性损伤是什么?急性损伤是什么?化疗 化疗是一种化学疗法.高剂量的甲基甲酸盐.利乌科沃林 (Leucovorin) 是一种蛋白质.葡萄糖酸酶的使用方法

更多相关视频

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.4K
Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

3.0K

相关实验视频

Last Updated: Jan 14, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.2K
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.4K
Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

3.0K

科学领域:

  • 在瘤学瘤学.
  • 药理学 药理学是指药理学的学科.
  • 腎臟病學 (nephrology) 是一種醫學專業.

背景情况:

  • 甲托雷克萨特 (MTX) 是一种抗代谢抗癌剂,用于各种剂量.
  • 高剂量甲状腺素 (HDMTX),>500 mg/m2,治疗各种癌症,包括白血病和骨肉瘤.
  • 毒性发生在HDMTX疗程的2%-39%中,严重病例约为2%.

研究的目的:

  • 强调MTX药理动力学和药理动力学的重要性.
  • 突出MTX抗癌活性的细胞机制.
  • 审查MTX诱导的损伤病理生理学和管理策略.

主要方法:

  • 关于MTX的药理动力学,药理动力学和毒性的文献综述.
  • 对MTX细胞机制的分析.
  • 对MTX毒性进行预防和管理策略的探索.

主要成果:

  • 延迟的MTX排泄和功能障碍可能导致严重的毒性.
  • 增加水分,高剂量leucovorin和葡萄糖酶是关键的治疗方法.
  • 有效的毒性管理可以改善癌症的预后和生存率.

结论:

  • 了解MTX的药理动力学和药理动力学是至关重要的.
  • 迅速识别和治疗MTX毒性至关重要.
  • 有效的管理策略可以提高患者的治疗结果和生存率.